Share Twitter LinkedIn Facebook Email Rafael Santana-Davila MD @valdesan Of Fred Hutchinson Cancer Research Center Discusses Lurbinecedin Data At ASCO Important & Encouraging/ Want To See It Replace Topotecan Based On Safety Profile & Move Into First Line & In Combos.
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read
Lurbinectedin: Enhancing Immunotherapy Efficacy in Small Cell Lung Cancer Small Cell Lung Cancer 3 Mins Read